Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) closed at $19.48 in the last session, up 1.30% from day before closing price of $19.23. In other words, the price has increased by $1.30 from its previous closing price. On the day, 0.99 million shares were traded. ARCT stock price reached its highest trading level at $19.7897 during the session, while it also had its lowest trading level at $18.81.
Ratios:
We take a closer look at ARCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on May 28, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $32.
On January 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $41.
On August 12, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $70.Leerink Partners initiated its Outperform rating on August 12, 2024, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 15 ’24 when Chivukula Pad sold 12,000 shares for $20.76 per share. The transaction valued at 249,121 led to the insider holds 435,334 shares of the business.
Chivukula Pad bought 12,000 shares of ARCT for $249,121 on Oct 15 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 528969632 and an Enterprise Value of 355309056. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.82 while its Price-to-Book (P/B) ratio in mrq is 2.29. Its current Enterprise Value per Revenue stands at 2.909 whereas that against EBITDA is -5.132.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.40, which has changed by -0.090569556 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $25.88, while it has fallen to a 52-week low of $8.04. The 50-Day Moving Average of the stock is 43.75%, while the 200-Day Moving Average is calculated to be 32.64%.
Shares Statistics:
According to the various share statistics, ARCT traded on average about 515.33K shares per day over the past 3-months and 922910 shares per day over the past 10 days. A total of 27.15M shares are outstanding, with a floating share count of 24.86M. Insiders hold about 8.44% of the company’s shares, while institutions hold 95.15% stake in the company. Shares short for ARCT as of 1753920000 were 4371328 with a Short Ratio of 8.48, compared to 1751241600 on 5039101. Therefore, it implies a Short% of Shares Outstanding of 4371328 and a Short% of Float of 24.94.
Earnings Estimates
The market rating for Arcturus Therapeutics Holdings Inc (ARCT) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.12 and low estimates of -$1.88.
Analysts are recommending an EPS of between -$1.04 and -$4.42 for the fiscal current year, implying an average EPS of -$2.36. EPS for the following year is -$1.74, with 8.0 analysts recommending between $1.41 and -$4.36.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $116.18M, while the lowest revenue estimate was $57.68M, resulting in an average revenue estimate of $92.22M. In the same quarter a year ago, actual revenue was $152.31MBased on 10 analysts’ estimates, the company’s revenue will be $109.99M in the next fiscal year. The high estimate is $279.39M and the low estimate is $14.63M.
